Recently, it was demonstrated that somatostatin analogs preferential for the SSTR5 subtype suppress PRL release from prolactinoma cell cultures by 30 -40%. These data supported the idea of somatostatin receptor subtype-specific control of PRL secretion in such tumors. The present study examines the quantitative profile of SSTRs messenger ribonucleic acid (mRNA) in 10 PRL-secreting tumors and correlates the expression with the ability of native somatostatins (SS14 and SS28), SSTR2 preferential analogs (octreotide and BIM-23197), and the SSTR5 preferential analog BIM-23268 to suppress PRL secretion. RT-PCR quantitative analysis showed a large predominance of SSTR5 mRNA [5648 Ϯ 1918 pg/pg glyceraldehyde-3-phosphate dehydrogenase (GAPDH)] vs. SSTR2 mRNA (148 Ϯ 83 pg/pg GAPDH). The SSTR1 transcript was also highly expressed in prolactinomas (1296 Ϯ 669 pg/pg GAPDH). SSTR5 mRNA expression correlated with PRL inhibition induced by both SRIF14 and SRIF28. Among the different analogs tested, only BIM-23268 produced inhibition of PRL release similar to that achieved with the native peptides. Its EC 50 for PRL suppression was 0.28 Ϯ 0.10 nmol/L. No additive effects on PRL suppression were achieved by cotreatment of the tumor cells with SSTR2 and SSTR5 preferential analogs. In the same tumor cell cultures, quinagolide, a potent dopamine agonist, produced a dose-dependent inhibition of PRL with an EC 50 at least 10 times lower than that of BIM-23268. Coincubation of quinagolide and BIM-23268, particularly in tumor cells resistant to dopamine agonist treatment, did not produce additive effects on PRL suppression. In conclusion, prolactinomas have a specific pattern of SSTR subtype mRNA expression (SSTR5 and SSTR1). SSTR5 expression is correlated to PRL regulation. These inhibitory effects are superimposable, at a higher concentration, to those of the dopamine agonists, but are not additive, particularly in the adenomas resistant to dopaminergic suppression of PRL release. (J Clin Endocrinol Metab 84: 3268 -3276, 1999) T HE RECENT molecular cloning of five human somatostatin receptors subtypes, SSTR1-5, has led to great interest concerning their respective roles, localization, and transduction mechanisms (1-5). Their role in the regulation of secretion and cell proliferation in endocrine and neuroendocrine tumors has been established through use of the synthetic octapeptide analogs, octreotide and lanreotide, in the treatment of pituitary and gastro-entero-pancreatic tumors in humans (6). One of the key question to be answered is whether specific patterns of SSTR subtype expression can be identified in different human tumors. Of equal importance is whether the observed SSTR subtypes are associated with a biological function that is of therapeutic relevance. The availability of the SSTR subtypes has resulted in the discovery and characterization of SSTR subtype-specific analogs that can be used as tools to address this important issue. Octreotide , lanreotide (BIM-23014), and octastatin (RC-160) have preferential affinity for SSTR2, but have some affinity for SSTR3 and -5 (7). The compound BIM-23268 was shown to be SSTR5 preferential (8). A selective agonist at somatostatin receptor subtype 1 has also been described (9). Finally, very recently, combinatorial chemistry proved useful to identify SSTR1-5-selective, nonpeptide, small analogs of somatostatin (10).
bition of PRL release similar to that achieved with the native peptides. Its EC 50 for PRL suppression was 0.28 Ϯ 0.10 nmol/L. No additive effects on PRL suppression were achieved by cotreatment of the tumor cells with SSTR2 and SSTR5 preferential analogs. In the same tumor cell cultures, quinagolide, a potent dopamine agonist, produced a dose-dependent inhibition of PRL with an EC 50 at least 10 times lower than that of BIM-23268. Coincubation of quinagolide and BIM-23268, particularly in tumor cells resistant to dopamine agonist treatment, did not produce additive effects on PRL suppression. In conclusion, prolactinomas have a specific pattern of SSTR subtype mRNA expression (SSTR5 and SSTR1). SSTR5 expression is correlated to PRL regulation. These inhibitory effects are superimposable, at a higher concentration, to those of the dopamine agonists, but are not additive, particularly in the adenomas resistant to dopaminergic suppression of PRL release. (J Clin Endocrinol Metab 84: 3268 -3276, 1999) T HE RECENT molecular cloning of five human somatostatin receptors subtypes, SSTR1-5, has led to great interest concerning their respective roles, localization, and transduction mechanisms (1) (2) (3) (4) (5) . Their role in the regulation of secretion and cell proliferation in endocrine and neuroendocrine tumors has been established through use of the synthetic octapeptide analogs, octreotide and lanreotide, in the treatment of pituitary and gastro-entero-pancreatic tumors in humans (6) . One of the key question to be answered is whether specific patterns of SSTR subtype expression can be identified in different human tumors. Of equal importance is whether the observed SSTR subtypes are associated with a biological function that is of therapeutic relevance. The availability of the SSTR subtypes has resulted in the discovery and characterization of SSTR subtype-specific analogs that can be used as tools to address this important issue. Octreotide (SMS-201-995), lanreotide (BIM-23014), and octastatin (RC-160) have preferential affinity for SSTR2, but have some affinity for SSTR3 and -5 (7). The compound BIM-23268 was shown to be SSTR5 preferential (8) . A selective agonist at somatostatin receptor subtype 1 has also been described (9) . Finally, very recently, combinatorial chemistry proved useful to identify SSTR1-5-selective, nonpeptide, small analogs of somatostatin (10) .
Although a great deal of work has been directed toward study of human pituitary adenomas and control of GHsecreting tumors (6) , little attention has been focussed on PRL-secreting tumors until the recent work of Shimon et al. (11) . This research demonstrated SSTR5 selectivity in the regulation of PRL secretion from prolactinoma cells tested in vitro with the SSTR5 preferential agonist, BIM23268. The present work was aimed at confirming the SSTR5 selectivity of human prolactinomas. We analyzed a larger population of prolactinomas in vitro to address the following questions. 1) What is the quantitative pattern of expression of the five SSTR subtypes? 2) Using endogenous somatostatins or preferential SSTR2 or SSTR5 peptides, which is the more potent PRL suppressor in prolactinomas? 3) Knowing the dominant role of dopamine (DA) and its agonists in PRL inhibition, how do the somatostatin agonists compare in the control of PRL hypersecretion by human prolactinomas? Our data show a SSTR5 and SSTR1 phenotype of human prolactinomas that seems more cell specific than tumor specific. The significance of the SSTR1 expression is presently unknown. The SSTR5 preferential agonist is equipotent to the native somatostatins but less effective than DA agonists in the control of PRL secretion. The suppressive effects of BIM-23268 on PRL secretion correlate with the SSTR5 quantitative expression of the various tumors tested.
Subjects and Methods Patients
The present study was approved by the ethics committee of the University of Aix-Marseilles (Aix-Marseilles, France) and was undertaken after informed consent was received from each patient. Ten patients (six women and four men), aged 28 -57 yr, with macroprolactinoma (n ϭ 8) or microprolactinoma (n ϭ 2) were studied. Their endocrine status and neuroradiological characterization of the tumors were documented before any treatment. Basal PRL levels were expressed as the mean of six consecutive measurements obtained every 4 h during a 24-h period. DA sensitivity was assessed by an acute test using a single oral 2.5-mg dose of bromocriptine (Parlodel, Novartis, Basel, Switzerland). Blood samples were withdrawn hourly for 4 h to measure PRL. The sensitivity to DA agonist was expressed as the percent decrease in PRL from the basal to the nadir value during the bromocriptine acute test. In seven patients (P1-P7), magnetic resonance imaging (MRI) revealed adenomas with a 9-to 25-mm maximal diameter either enclosed in the pituitary fossa or with moderate suprasellar extension. These patients were operated on using transsphenoidal surgery, and postsurgical normalization of PRL levels was achieved. In contrast, patients 8 -10 presented with highly invasive macroadenomas and received, initially, treatment with quinagolide (Norprolac, Novartis), with the dosage rapidly increased up to 150 g/day. After 2-3 months, due to partial inhibition of hyperprolactinemia, the quinagolide daily doses were, according to tolerance, increased up to 300 -450 g/day. In no case did any of these three men achieve normal PRL values during long term DA agonist therapy. Repetitive MRI follow-up showed no evidence of tumor shrinkage in these three patients. Such long term observations characterized the subclass of patients presenting with prolactinomas resistant to DA agonists therapy (12) . Subsequently, due to either the persistence or the worsening of tumoral symptoms, patients 8 -10 underwent decompressive partial tumor removal by transfrontal neurosurgery. The clinical endocrine and morphological status of each patient is summarized in Tables 1 and 2 .
Hormone assays PRL and GH were measured using commercial kits (Immunotech, Marseilles, France; Medgenix Diagnostics, Fleurus, Belgium). Normal values for PRL ranged from 1-24 g/L in women and from 1-17 g/L in men. Among the 10 patients, none presented with GH or insulin-like growth factor I values over the normal range, ruling out any somatomammotropin-secreting adenoma.
Immunocytochemistry
Tumoral tissue obtained at transsphenoidal (n ϭ 7) or transfrontal (n ϭ 3) neurosurgery was in part placed in 10% formalin and embedded in paraffin. Immunocytochemistry was carried out on 5-m sections using a monoclonal antibody directed against human PRL (1:200 dilution; Immunotech), and a human GH polyclonal antiserum (1:2000; DAKO Corp., Hamburg, Germany). The antihuman LH␤, FSH␤, TSH␤, and ␣-subunit monoclonal antibodies were obtained from Immunotech. Automated immunohistochemistry with avidin-biotin peroxidase complex was performed using a Ventana 320 device (Ventana Systems, Strasbourg, France). The intensity of cell labeling was expressed as the percentage of cell labeling by a given antibody as observed by the same investigator.
Detection of SSTRs
Ribonucleic acid (RNA) preparation. Total RNA was extracted from 15-30 mg tissue from each tumor using the SV total RNA isolation system (Promega Corp., Lyon, France). To prevent any contamination by genomic DNA, the RNA samples were treated with 30 U ribonucleasefree deoxyribonuclease I (Roche Molecular Biochemicals, Mannheim, Germany) at 37 C for 90 min, followed by phenol-chloroform extraction and ethanol precipitation. Depending on the tumor, 5-36 g RNA were obtained. Combined quantitative RT-PCR. Total RNA was reverse transcribed into complementary DNA (cDNA) using 1 g hexamers (Pharmacia Biotech, Orsay, France) and Moloney murine leukemia virus reverse transcriptase as described by the manufacturer (Life Technologies, Inc., Paris, France). The 5Ј-exonuclease (Taq Man; Roche Molecular Systems, Inc., Alameda, CA) assay that produces a direct proportional readout for the progression of PCR reactions was used (13) . For quantitation of the data, SSTR messenger RNA (mRNA) levels were, in the same reaction, normalized to the GAPDH mRNA levels. The control GAPDH primers were as follows: sense, 222-240; antisense, 322-303; and probe, 277-301. For each measurement, three independent RT-PCR analyses were performed. To create standard curves for each SSTR mRNA and GAPDH mRNA, RNAs were produced by in vitro transcription from linearized templates corresponding to SSTRs and GAPDH cDNA constructs using T7 or T3 polymerases as previously described (14) . The synthesized RNAs were reverse transcribed to cDNA for each parameter as described above.
Taq Man PCR assay conditions for SSTR and GAPDH mRNAs.
Using the fluorogenic probes for SSTR receptors and GAPDH with the experimental conditions defined above, we obtained a linear relationship between the RNA concentration (previously transcribed into cDNA) and the fluorescent signal (⌬RQ) for SSTR and GAPDH RNAs in 25-250 pg DNA target. For each unknown sample, we determined the ⌬RQ values for both genes, and the results were expressed as picograms of SSTR per pg GAPDH.
Cell culture studies
After surgery, fragments of each tumor were dissociated by mechanical and enzymatic methods (15) , and 15 ϫ 10 3 dispersed cells were plated in multiwell culture dishes coated with extracellular matrix from bovine endothelial corneal cells. Tumoral cells were cultured in DMEM supplemented with 10% FCS for 4 days before the start of the experiments. Subsequently, the cells were washed and cultured in serum-free defined DMEM supplemented with antibiotics, insulin, transferrin, and selenium as previously described (15) . The effects of various doses of the DA agonist quinagolide (selected while patients 8 -10 were treated with this drug) and of the somatostatin agonists, SRIF14, SRIF28, BIM-23268, BIM-23197, and octreotide, on inhibition of PRL release were measured over an 8-to 14-h period, as indicated in Results. Each drug concentration was tested in quadruplicate culture wells (Costar 3524, Brumath, France). Quinagolide and octreotide were supplied by Novartis. Somatostatin-14 and somatostatin-28 were purchased from Sigma Chemical Co. (Saint-Quentin Fallavier, France). BIM-23268 and BIM-23197 were provided by Biomeasure, Inc. (Milford, MA). Quinagolide was initially prepared as a 10 Ϫ3 mol/L solution in 70% ethanol. The somatostatin analogs were dissolved in 0.01 mol/L acetic acid and 0.1% purified BSA (Life Technologies, Inc., Cergy Pontoise, France). The drugs were initially prepared as a 10 Ϫ3 mol/L solution and stored at Ϫ80 C. At the end of experiments, culture media were collected and stored frozen for PRL and GH measurements.
Statistics
The results are presented as the mean Ϯ sem. Statistical significance was determined by Mann-Whitney test. To measure the strength of association between pairs of variables without specifying dependencies, Spearman order correlations were run. P Ͻ 0.05 was considered significant in all tests.
Results

SSTR mRNA expression in prolactinomas
RT-PCR quantitative analysis demonstrated, in all prolactinomas, the presence of SSTR5 mRNA, which was the dominant receptor subtype in 7 of 10 tumors (Fig. 1) . The level of SSTR5 expression varied from 38 -17,000 pg/pg GAPDH regardless of tumoral status, i.e. invasive or noninvasive adenomas. The SSTR2 transcripts, although detected in all tumors, were at a much lower level of expression. The mean value of 148 Ϯ 83 pg/pg GAPDH for SSTR2 mRNA contrasted sharply with that of 5648 Ϯ 1918 pg/pg GAPDH obtained for SSTR5 mRNA. In only one resistant prolactinoma (P8), expressing very low levels of SSTR transcripts, was the expression of SSTR2 mRNA slightly greater than that of SSTR5 transcripts. The mean level of expression of SSTR1 transcripts in this series was 1296 Ϯ 669 pg/pg GAPDH, and it was present to varying degrees in all tumors. In 4 prolactinomas (P1, P3, P6, and P10), regardless of whether they were DA-resistant or -sensitive tumors, the expression of SSTR1 mRNA was equivalent to or greater than that of SSTR5 mRNA. Finally (data not shown), the expression at very low levels (extremes, 11-52 pg/pg GAPDH) of SSTR3 and SSTR4 mRNAs was detected in a minority (3 of 10) of these tumors: P6, P10 for SSTR3 (ranging from 49 -52 pg/pg GAPDH) and P6, P7, and P10 for SSTR4 (ranging from 11-35 pg/pg GAPDH). According to the individual profiles, represented in Fig. 1 , when SSTR5 mRNA was the largely predominant subtype (P4, P5, and P7), the SSTR1 transcript was poorly expressed. Conversely, P1 and P3 macroadenomas with high levels of SSTR1 mRNA presented with low levels of SSTR5 mRNA. In this series, SSTR transcript expression was not different between invasive and noninvasive tumors. The only exception (case P8) was a highly aggressive tumor (leading after 2 successive interventions to death). It was characterized by minimal SSTR transcript expression. This pattern of dedifferentiation was not observed in the 2 other DA-resistant adenomas.
SSTR mRNA and PRL release inhibition
In all 10 prolactinoma cell cultures, the effects of SRIF14, BIM-23268, BIM-23197, and octreotide were studied over an 8-h incubation period. As shown in Table 3 , in all cultures, the native somatostatin SRIF14 produced a 52 Ϯ 7% maximal inhibition of PRL release. A superimposable inhibitory effect was also achieved by maximal concentrations of the SSTR5 preferential analog BIM-23268. In contrast, BIM-23197 inhibited PRL release by 23 Ϯ 5%. Interestingly, a 46 Ϯ 2% inhibition of PRL release with BIM 23197 occurred in cultures of tumors P4, P6, and P8, which were the tumors expressing the highest levels of SSTR2 mRNA. In all cases, the octreotideinduced inhibition of PRL was weak or nonsignificant (12 Ϯ 3%). The degree of PRL inhibition by SRIF14 and BIM-23268 and the level of SSTR5 mRNA were correlated (P Ͻ 0.04 and P Ͻ 0.08, respectively). No correlation between SSTR2 (or SSTR1) mRNA expression and inhibition of PRL release was observed in the series. Thus, these results support the observation of an inhibitory effect of the SSTR5 preferential agonist, which correlates with the expression of SSTR5 transcripts in prolactinomas.
The dose-response inhibition of PRL by BIM-23197 and 23268 in prolactinomas was examined in six tumors (Fig. 2) . The SSTR5 preferential compound BIM-23268 was a more potent inhibitor of PRL suppression than the SSTR2-preferring compound BIM-23197 in all instances. The EC 50 values for PRL suppression were 0.23 Ϯ 0.19 and 0.44 Ϯ 0.24 nmol/L, respectively, for the three DA-sensitive and the three DA-resistant prolactinomas. In experiments with one tumor (P9), a biphasic PRL response was observed as a 45% stimulation of PRL release at lower concentrations of BIM-23268, followed by a 49% inhibition of PRL release at higher concentrations. Finally, the SSTR2 preferential analog BIM-23197 was ineffective in suppressing PRL secretion in four of six tumor cell cultures. In the two BIM-23197-responsive tumors, one sensitive and one resistant (P4 and P8), BIM-23197 also produced a dose-related suppression of PRL, but at concentrations 50-to 100-fold higher than that required by BIM-23268.
Quinagolide vs. somatostatin agonist PRL suppression in prolactinomas
In the same 10 tumors, classified as either sensitive (n ϭ 7) or resistant (n ϭ 3) to dopaminergic drugs, we compared the effects of maximal doses of quinagolide and SS agonists, either alone or in combination, on inhibition of PRL release in vitro (Fig. 3) . In controls (medium alone), GH release from the tumor cells was undetectable in 9 of 10 cases. In only 1 tumor (P6) did GH release (0.2 vs. 4 ng/8 h for PRL) represent 5% of the hormone secretion. The mean maximal inhibitory effects of dopaminergic and somatostatinergic agonists are presented separately for the 7 DA-sensitive and the 3 DAresistant tumors. In the sensitive tumors, as expected, the DA agonist quinagolide induced a 75 Ϯ 6% inhibition of PRL release. In comparison, a 54 Ϯ 8% inhibition was achieved by SRIF14, SRIF28, and BIM-23268. In no instance, even in the 3 tumors expressing the highest levels of SSTR2 mRNA, was any significant additive effect of BIM-23197 and BIM-23268 c Maximal PRL inhibition achieved after an 8-h incubation period, with 10 nmol/L of the different drugs, expressed as the mean (n ϭ 4) percent PRL suppression compared to controls (medium alone).
observed. In the 3 experiments performed with resistant prolactinomas, as expected, the maximal inhibition of PRL release with quinagolide was only 44 Ϯ 4%. As previously observed in prolactinomas sensitive to DA, a superimposable inhibition of PRL was achieved with the native somatostatins and BIM-23268. Again, no additive inhibitory effects on PRL inhibition occurred when BIM-23197 and BIM-23268 were combined in the resistant tumor cell cultures.
To compare the relative potencies of DA and SSTR agonists on PRL inhibition, quinagolide and BIM-23268 were added at different concentrations in five different tumor cell cultures from DA-sensitive and DA-resistant adenomas (Fig.  4) . In all tumors, quinagolide and BIM-23268 induced a dosedependent inhibition of PRL release. The mean maximal inhibition of PRL release was obtained at 1 and 0.1 nmol/L, respectively, with BIM-23268 and quinagolide. The mean dose-response curve elicited by BIM-23268 required higher concentrations of this analog compared to those of quinagolide. In the three tumor cell cultures sensitive to quinagolide, the EC 50 was 0.03 Ϯ 0.01 nmol/L with quinagolide vs. 0.23 Ϯ 0.23 nmol/L with BIM-23268. A superimposable pattern was also obtained with quinagolide and BIM-23268 in the two resistant tumors studied. These data demonstrate a better efficacy, achieved at lower concentrations, with the DA superagonist quinagolide than with the SSTR5 agonist.
DA and SSTR agonist additivity?
To know whether the combination of the DA agonist quinagolide and the SSTR5 preferential agonist BIM-23268 could produce a synergistic effect on PRL inhibition, both drugs, alone and in combination, were tested at various doses in one DA-sensitive and one DA-resistant prolactinoma. In these experiments, the dose response to BIM-23268 was determined in the presence of quinagolide at a concentration previously determined to correspond to its EC 50 for PRL suppression (Fig. 5) . The maximal inhibitory effects on PRL release were 82% and 40% in cell cultures from the DA-sensitive and DA-resistant adenomas, respectively. At 1-10 nmol/L of either quinagolide or BIM-23268, no additivity could be demonstrated by combining the two compounds. In the DA-sensitive adenoma, partial additivity occurred at 10
Ϫ9 mol/L concentrations of BIM-23268 in combination with quinagolide at 10 Ϫ12 mol/L. A similar slight additivity was also observed in the resistant cell culture adenoma when the cells were cotreated with quinagolide at 10 Ϫ10 mol/L and BIM-23268 at 10 Ϫ10 or 10 Ϫ9 mol/L.
Discussion
Since 1985, different studies have been undertaken to address the biochemical characterization of the SSTRs in human pituitary adenomas. Indeed, most of the attention focussed on GH-secreting tumor due to the therapeutic efficacy of the somatostatin analogs octreotide and lanreotide in acromegaly. Initially, binding studies using 125 I-[Tyr]somatostatin demonstrated SRIF-specific binding in prolactinoma (16) . However, the maximal specific SRIF binding (37 Ϯ 9 fmol/mg protein) was 4 times lower than that measured in membranes from GH-secreting adenomas. In contrast, SRIF receptor autoradiography, using a synthetic [
125 I]octapeptide, did not reveal significant amounts of SRIF binding in most prolactinomas (17) . Such a discrepancy already suggested that prolactinomas expressed different SSTR than those that recognize the synthetic analog, octreotide. The identification of five SSTR subtypes led to the search for tissue-specific patterns for expression of these receptor subtypes (18) . Using RT-PCR, ribonuclease protection assay, or in situ hybridization (19 -23) , the SSTR mRNA subtypes have been qualitatively analyzed in 21 prolactinomas. In such tumors, 84% were found to express human SSTR1, 63% were found to express human SSTR2, and 71% were found to express human SSTR5 (24) . However, these three transcripts were also found to be expressed in the normal human pituitary as well as in GH-secreting tumors (21); thus, no specific pattern of expression could be assigned to PRL-secreting tumors. Nevertheless, from different studies by Greenman and Melmed (25) , it appeared that SSTR2 was predominantly expressed in GH-secreting adenomas, whereas SSTR-1 was present in most prolactinomas studied. Our analysis allowed the quantification of human SSTR1, -2, and -5 mRNAs in prolactinomas. Indeed, only rarely were the three subtypes simultaneously expressed at a comparable level, as is generally true for all human tumors (26) . Despite variable individual patterns, in our tumors SSTR5 and SSTR1 transcripts were by far the most predominant.
The dominant expression of SSTR5 in prolactinomas is in accord with the recent findings of Shimon et al. (11) , who demonstrated the functional selectivity of SSTR5 agonists in prolactinomas. Our data clearly confirm the preferential efficacy of BIM-23268 on PRL inhibition. BIM-23268 has been shown in studies with membranes from transfected CHO-K1 cells expressing the different SSTR subtypes to have a binding affinity of 0.37 nmol/L (EC 50 ) for SSTR5, 40-fold greater than that for SSTR2 (8) . SSTR2 mRNA was weakly expressed in the majority of prolactinomas, in contrast to its constant expression in GH-secreting tumors (25) . These data explain the inability of radiolabeled octreotide to visualize SRIF receptors in prolactinomas, as previously observed (17) , as this agonist acts preferentially through the SSTR2 subtype. Similarly, in our cell culture studies, BIM-23197, which acts essentially through the SSTR2 subtype (27) , was largely ineffective in suppressing PRL secretion.
The SSTR1 subtype was consistently found to be coexpressed with the SSTR5 subtype in all 10 prolactinomas stud- ied. It was not correlated to either the level of PRL secreted in culture or the tumor mass evaluated by MRI (data not shown). The 2 cases that expressed the highest levels of SSTR1 mRNA (P6 and P10) were classified as either DAsensitive or DA-resistant tumors, respectively. According to previous studies that used RT-PCR analysis, SSTR3 and SSTR4 mRNAs are poorly expressed or absent in prolactinomas. SSTR3 expression was only observed in 4 prolactinomas (20, 23) , but was not found in 13 other tumors (21, 22) . Similar weak expression of SSTR3 was observed in a third of our tumors. Finally, the tumoral pattern of SSTR5 and SSTR1 expression in prolactinomas diverges from the pattern of SSTR5 and SSTR2 mRNAs expressed in GH-secreting tumors (25) . Such a difference can be interpreted either as a tumorspecific or a cell-specific phenotype. The cell-specific phenotypic interpretation is supported by recent data concerning the cell-specific localization of the SSTR subtypes in adult rat anterior pituitary cells (28, 29) . Using double immunostaining with antibodies raised against the SSTR2-5 subtypes, they visualized both SSTR5 and SSTR2 receptors in the majority of GH cells, whereas in lactotrophs, SSTR5 labeling was largely dominant, and SST2A was found in only a few lactotrophs. Presently, we are lacking similar observations for the human adult pituitary. In one study (30) mRNA hybridization, receptor binding, and receptor immunocytochemistry methods were shown to be correlated. Consequently, it may suggest that our mRNA quantification correlates with expression of the SSTR subtypes at the cell membrane level. The correlation between SSTR5 mRNA levels and the effects of BIM-23268, on the one hand, and SSTR2 mRNA levels and the effects of BIM-23197, on the other hand, confirm that mRNA reflects the level of expression of their respective functional receptor subtypes. In contrast, we could not associate the presence of SSTR1 mRNA with any specific phenotype, questioning the functional significance of the presence of this mRNA.
Due to the absence of a clear suppressive effect of somatostatin infusion in most patients with hyperprolactinemia (31), little attention has been given to the in vitro suppression of PRL by SRIF or its analogs in prolactinoma cells. In 2 in vitro studies examining 10 prolactinomas, 10 -100 nmol/L SRIF14 produced a maximal suppression of PRL secretion of 32% vs. the control value (32, 33) . More recently, Hofland et al. (23) compared the inhibitory effects of the DA agonists (bromocriptine and/or quinagolide) vs. those of somatostatin and 3 octapeptide somatostatin analogs in 7 prolactinomas. They concluded that, overall, PRL release was consistently inhibited by the DA agonists, but was only partially suppressed by SRIF28 in four cultures. The PRL-suppressive effects of the somatostatin analogs octreotide, lanreotide, and RC-160 were modest if any. Interest in the somatostatinergic control of prolactinomas has been recently increased due to the work of Shimon et al. (11) , who showed that only the SSTR5-selective analogs, such as BIM-23268, are effective in suppressing PRL secretion by prolactinoma cells. In only 4 tumors (obtained from men harboring invasive macroadenomas) did BIM-23268 inhibit PRL release by 30 -40%, and it proved in 2 cases to be more effective than SRIF14. Our data confirm and extend these previous observations concerning the selective efficacy of BIM-23268 on PRL suppression. At maximal concentrations, this compound produced a 26 -90% inhibition of PRL release depending on the tumor; however, it was never stronger than the suppression obtained with the native, endogenous somatostatins. In contrast to the earlier study (11) , no stimulatory effect of the SSTR2 preferential analogs was observed when used at maximal concentrations. In addition, in those tumors expressing SSTR2 mRNA, a partial suppression of PRL secretion was observed with BIM-23197. In no instance was additive suppression of PRL shown by the combination of the SSTR5 and SSTR2 preferential agonists. These data support the concept that the SSTR5 subtype is the primary SSTR subtype controlling PRL secretion. The EC 50 for PRL suppression by BIM-23268 was 0.28 Ϯ 0.10 nmol/L. The rather large se serves to emphasize the large spectrum of sensitivity of individual tumors to soma- tostatinergic regulation. Similar observations were previously made using DA agonists in prolactinoma cultures (33) . A subclass of 5-18% patients is characterized as resistant to DA agonist therapy (34) . Such resistance, often associated with continued tumor growth, results from deficient regulatory mechanisms of the adenomatous cells. The major abnormality is a dramatic decrease in the number of DA D2 receptors, explaining the only partial effect of DA agonists on adenylyl cyclase activity. In such tumors it was of interest to know whether the SSTR5 agonist would be effective when the DA superagonist quinagolide was not (35) . In the 3 resistant prolactinomas studied, similar partial PRL suppression with both quinagolide and BIM-23268 argues against such a proposition. It is likely that, in these resistant tumor cells, a common defect lies beyond the receptors that prevent inhibition of adenylate cyclase activity or of other transducing mechanisms. Quinagolide was more effective at lower concentrations than BIM-23268 in suppressing PRL secretion (EC 50 ϭ 0.012 Ϯ 0.009 nmol/L). Even cotreatment of the tumor cells with both compounds did not achieve, at least at maximal concentrations, a significant additive effect on PRL inhibition. Taken together, these findings indicate that in prolactinomas as well as in other tumors, such as breast or prostate neoplasms, drug or hormone resistance identifies a subset of tumors that has lost their differentiated, normal functions, i.e. in the case of prolactinomas, regulation of PRL secretion (32) . Unless future tumor studies demonstrate that in some prolactinomas PRL regulation is preserved by SSTR5 agonists but is resistant to dopaminergic control, the usefulness of SSTR5-selective agonists in the treatment of such tumors seems of modest interest. At present, the neurosurgical approach remains the only palliative therapy for DAresistant prolactinomas that undergo progressive tumor growth despite long term treatment with high doses of DA agonists. Finally, if the dominant role of SSTR5 on PRL release is clearly established, we have yet to understand the significance of its association with SSTR1 expression in prolactinomas. This receptor seems unable to mediate inhibition of cAMP formation (5) . The recent availability of SSTR1-specific analogs (9) will certainly provide information about possible cross-talk between SSTR1 and SSTR5 in prolactinoma cells and their respective involvement in the control of tumor growth through the regulation of mitogen-activated protein kinase pathways (36) .
On the other hand, it was indeed mandatory to properly define the SSTR receptor phenotype of lactotroph cells to understand the roles of the different SSTR in GH-secreting adenomas, which present in at least 50% of cases with mixed GH-PRL cell populations. Work is in progress in our group concerning the functional expression of SSTR in such pituitary adenomas.
